Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Woodcock Outlines Priorities For Next US FDA Commissioner

Executive Summary

Along with the pandemic, user fees, IT upgrades and nutrition issues should be at the top of the list, the acting commissioner said.

You may also be interested in...



Califf: More Expedited Approvals Mean US Clearance Only The Beginning Of Learning About Medical Products

The US FDA commissioner said increased use of expedited approval pathways will help spur clinical research system reform.

Thinking Post-COVID: How Will US FDA Transition Drug, Vaccine EUAs To Full Approvals?

Sponsors seek clarity about the transition process, which could last a year or longer.

Dr. Califf Returns To US FDA: What To Do First?

Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel